Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments like spironolactone often require lifelong use to maintain results. Stopping the medication can lead to increased testosterone levels and potential hair loss.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The user experienced improved libido and erections after reducing DHT levels with 0.5mg of dutasteride once a week, despite previous side effects from finasteride. They are also on testosterone replacement therapy and have not noticed major personality changes.

A 24-year-old male using topical finasteride for hair loss is experiencing thinning despite treatment and has high estrogen levels. He is seeking advice on whether high estrogen could be causing hair loss and how others with high estrogen levels have addressed it.

Switching from finasteride to a generic dutasteride led to unexpectedly high DHT levels, prompting a switch to a reputed brand and consideration of softgel capsules for better absorption. The user plans to retest DHT levels and may return to finasteride if issues persist.

The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.

A user is experiencing worsening hair loss despite using finasteride, PRP treatments, and supplements like vitamin D, biotin, zinc, and iron. They are seeking advice on whether to continue with finasteride, increase the dosage, or try additional PRP sessions.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The efficacy of low doses of finasteride to reduce scalp DHT, and whether studies showing a 61% reduction are reflected in actual results. Replies discussed hair growth as an unintended consequence of minoxidil and finasteride use, as well as self-selective bias, potential side effects, and that studies measure effectiveness by hair count changes rather than DHT inhibition.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

Finasteride users report reduced libido and increased hair shedding initially, but some see these as temporary or manageable side effects. Vitamin E and D-3 supplements are discussed as potential aids for libido and mood.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.

Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.

Finasteride significantly increased testosterone levels for the user, with no major side effects except watery semen, which was resolved with zinc supplements. The user's hairline stopped receding and slightly improved.

User tried topical fin, dut, min, tret, hydrocortisone, microneedling, nizoral, collagen, propidren supplements, and laser helmet for hair loss with slow progress. They ask if topical spironolactone is a safer, effective alternative to RU for suppressing testosterone and treating hair loss in men.

The user shared their experience with hair loss treatments, including oral and topical Finasteride and Minoxidil, and detailed various blood test results to track hormonal changes. They noted that while DHT levels initially decreased with topical Finasteride, they later increased, but they observed positive results in hair growth.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

A 22-year-old male experiencing diffuse hair thinning has been using finasteride, initially at 0.5mg and then 1mg daily, but sees no improvement. Despite correcting a vitamin D deficiency and noticing some new hair growth, he questions the effectiveness of finasteride.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.